Navigation Links
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Date:1/14/2008

- MAA submission based on data from largest Phase 3 study conducted in MDS

- Vidaza therapy confers highly significant 9.4 month median overall

survival advantage compared to conventional care regimens - Two year overall survival rate of 50.8% for Vidaza compared to 26.2% for

conventional care regimens

BOULDER, Colo., Jan. 14 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced the submission of a MAA with the European Medicines Agency (EMEA) for Vidaza(R) (azacitidine for injection) in the treatment of patients with higher-risk MDS in the European Union (EU).

"We are pleased to submit this application to the EMEA, given the highly compelling data for Vidaza in the treatment of MDS," said Patrick J. Mahaffy, Pharmion's president and chief executive officer. "Vidaza is the only hypomethylating agent, and, in fact, the only drug to have shown an improvement in overall survival in this indication, and we believe it will become the standard of care throughout Europe for higher-risk MDS."

"Our study results presented late last year at the American Society of Hematology meeting confirm that Vidaza should be considered first-line therapy for patients with higher-risk MDS," said Pierre Fenaux, M.D., Professor of Hematology at the University of Paris, and Head, Department of Clinical Hematology, Hopital Avicenne, France, and principal investigator of the Phase 3 study. "Overall survival is the gold standard by which clinical benefit should be measured for patients, and these data demonstrate the tremendous benefit that Vidaza can provide these patients; this represents a significant advance in the treatment of MDS patients."

Vidaza has been designated as
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
2. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
3. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
4. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
5. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
6. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
7. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
8. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013  BioRestorative Therapies, Inc. ("BRT" or the ... on developing stem cell based therapies for various personal ... its President and CEO, will be presenting at the ... be held on Thursday, May 30, 2013 at the ... in New York City.  Mr. Weinreb,s presentation will take ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, ... secondary analysis of its double-blind, randomized, controlled Phase ... a gene therapy product designed to deliver the ... analysis identified a more robust response to CERE-120 ... to treatment relative to those diagnosed 10 years ...
(Date:5/21/2013)... MONROVIA, Calif. , May 21, 2013 ... leading developer, manufacturer and marketer of minimally invasive ophthalmic ... upcoming investor conferences to review the Company,s recent financial ... STAAR Surgical will present at the 38 ... Boston at the Westin Waterfront ...
Breaking Medicine Technology:BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5STAAR Surgical To Present At Upcoming Investor Conferences 2
... COLLEGEVILLE, Pa., and TARRYTOWN, N.Y., May 22 ... ), and Progenics,Pharmaceuticals, Inc. (Nasdaq: PGNX ), ... with investigational oral and,intravenous formulations of RELISTOR(TM) (methylnaltrexone ... phase 2 trial, evaluated the effects of,an oral ...
... LAS VEGAS, May 22 CardioVascular,BioTherapeutics, Inc. (OTC Bulletin ... Christopher Moore to be the sponsor and general,partner of ... of,$1 million and up to $10 million of the ... am extremely impressed with CVBT,s wound healing drug, which ...
Cached Medicine Technology:Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 2Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 3Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 4Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 5Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 6Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 7Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 2Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 3
(Date:5/21/2013)... Spring is the perfect time to ... filled with whole foods to weather perfect for outdoor ... season the nutrition experts at Brilliant Nutrition highlight five ... , 1. Eating Locally, With the abundance of fresh ... and explore, spring is a great time to take ...
(Date:5/21/2013)... Feed additives have now become an ... chain. Most of the feed additives are used in ... and powders. There are variety of feed additives available ... upon the type of animal and feed. Nutritional feed ... essential nutrition to the animal in order to gain ...
(Date:5/21/2013)... Daily Gossip Magazine published well-documented articles that are ... people informed on the latest weight loss methods by publishing ... in-depth review of Kyle Leon’s Customized Fat ... want to lose weight or stay in shape with the ... was created by a popular fitness trainer, Kyle Leon, who ...
(Date:5/21/2013)... DISCcert has served the training industry for ... DISC applications at the July 25 & 26th ... July 25 & 26th DISC certification in San Diego, ... DISC. The time-tested, proven support materials will include valuable ... training materials ; worksheets, handouts, learning activities, power-points ...
(Date:5/21/2013)... 2013) Prostaglandin analogues (PGAs), drugs which lower intraocular ... people with glaucoma, but their use is not without ... dryness, changes in eye color and other side effects. ... also cause upper and lower eyelid drooping and other ... described in PLOS ONE . , Researchers from ...
Breaking Medicine News(10 mins):Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 2Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 3Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 3Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 4Health News:Customized Fat Loss Plan Review and Diet Secrets Revealed By Daily Gossip Magazine 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Glaucoma drug can cause droopy eyelids 2
... Inc. (Nasdaq: MSON ), a developer of ... is used for the ablation of tumors and worldwide ... has purchased three patents associated with High Intensity Focused ... relate to HIFU transducer arrays method of fabrication, ultrasonic ...
... with rheumatic diseases want more information and better communication ... their conditions, according to the results of a new ... of the European League Against Rheumatism in Copenhagen, Denmark. ... understand the importance of addressing sexual health with their ...
... Friday 12 June 2009: After five years of receiving ... spondylitis (AS) showed substantial clinical benefit (ASAS40, ASsessment in ... at five years, 78.4% of AS patients had no ... junction between tendon and bone). Over this period, patients ...
... CHICAGO, June 12 Germany ... by the eastern federal states.,This is in large part ... despite the economic crisis. American investor interest in,Germany remains ... Nordex AG shared their success stories at the "How,Far ...
... , Travelers Turn to InsureMyTrip.com for Coverage Protection and ... Stating ,the scientific criteria for an influenza pandemic have ... declared the A(H1N1) virus, commonly referred to as Swine ... http://www.newscom.com/cgi-bin/prnh/20070529/NETU076LOGO ) , , "Particularly ...
... 12 June 2009: 92.8% of patients with systemic lupus ... both their physical and emotional quality of life (QoL), ... today at EULAR 2009, the Annual Congress of the ... analysis revealed that depression was the most significant factor ...
Cached Medicine News:Health News:Misonix Announces the Purchase of Patents From ProRhythm, Inc. 2Health News:Misonix Announces the Purchase of Patents From ProRhythm, Inc. 3Health News:Better access to info and dialogue with HCPs on sexual issues for rheumatology patients 2Health News:Better access to info and dialogue with HCPs on sexual issues for rheumatology patients 3Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 2Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 3Health News:American Investors Highlight Successes in Eastern Germany 2Health News:World Health Organization Declares A(H1N1) Pandemic 2Health News:World Health Organization Declares A(H1N1) Pandemic 3Health News:Anxiety and depression lower quality of life in majority of systemic lupus erythematosus patients 2
... Adjustable Post-Operative Pin Knee Brace (POP) for ... associated with ACL, PCL, MCL, and LCL ... extension in 7 increments. Can be locked ... increases compliance. Breakaway hinge bar converts long ...
... The Aircast Patellar Brace is a ... unique "horseshoe" shaped aircell stabilizes the patella ... maintain the position of the patella. During ... helping to reduce swelling and pain. A ...
... Pediatric Knee/Elbow Cryo/Cuff is specifically designed to treat ... the therapeutic benefits of controlled compression to minimize ... Due to the unique design of the cuff, ... knee and elbow of the patient. The Pediatric ...
... therapeutic benefits of controlled compression to minimize hemarthrosis ... cuff is anatomically designed to completely fit the ... available in three sizes for adults and is ... children 1 - 7 years of age. A ...
Medicine Products: